DUBLIN--(BUSINESS WIRE )--The "U.S. Gene Therapy Market - Industry Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering

U.S. gene therapy market is expected to grow at a CAGR of 43.44% during 2022-2027. The US gene therapy market would realize an absolute growth of over 771.00% in terms of revenue between 2021 and 2027.

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this U.S. Gene Therapy Market Report

The market is witnessing steady growth due to the increased availability of funding from various public and private institutes. In addition, there is increased support from regulatory bodies for product approvals and providing fast-track designations to the products, which encourages vendors to manufacture the products at a faster rate.

U.S. GENE THERAPY MARKET SEGMENTATION

Among product type segments, the CAR-T therapy segment dominates the US gene therapy market, accounting for a share of 51.96%, followed by non-CAR-T therapy with 48.04% in 2021.

Based on the vector type, the US gene therapy market is segmented into retroviral and others. The other segment includes adeno virus, adeno-associated virus, herpes simplex virus, and non-viral vectors. The retroviral segment accounted for a major share of 51.96% and others with 48.04% in 2021

Based on end-users, the market is segmented into hospitals, cancer care centers, and academic & research centers. The hospital segment dominated the market with a share of 56.45%, followed by cancer care centers with 35.87%.

The US gene therapy market is witnessing the high competition among the vendors. The market is characterized by the presence of various pharma and various small-scale companies. With the changing market landscape, the competition is turning intense due to some recent high-value M&As.

8 Reimbursement for Gene Therapy in US

9 Regulatory Scenario for Gene Therapy Products

9.2 Clinical Trial Process for Gene Therapy

10 Commercial Gene Therapy Products in US

11 Gene Therapy Products in Pipeline

12.1 Increasing Market Access for Gene Therapies

12.2 Introduction of Universal Car-T Therapy

12.4 Increased Funding for R&D Activities of Gene Therapies

13.1 Increase in CMOS to Manufacture Gene Therapies

13.3 Product Launches & Regulatory Approvals

13.4 Regulatory Support & Special Designations for Gene Therapies

14.1 High Cost of Gene Therapy Products

14.2 Limitations of Gene Therapy Products

14.3 Availability of Alternative Therapeutics & Withdrawal of Products

16.1 Market Snapshot & Growth Engine

17.1 Market Snapshot & Growth Engine

18.1 Market Snapshot & Growth Engine

19.1 Market Snapshot & Growth Engine

20.1 Market Snapshot & Growth Engine

For more information about this report visit https://www.researchandmarkets.com/r/j4egrk

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900